Induction therapy in mantle cell lymphoma is rapidly evolving. How do you treat your patients with MCL?
Ibrutinib and acalabrutinib are both active in relapsed MCL. Read how I consider safety, long-term data, and patient preferences when deciding between these BTK inhibitors.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with newly diagnosed and relapsed/refractory mantle cell lymphoma with those of 5 renowned experts.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.